18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

24 August 2020 - Event

4th AMR Conference Novel Antimicrobial & AMR Diagnostics

IMPORTANT UPDATE: Due to the Coronavirus situation, the AMR Conference had to be postponed to 24–25 August in Basel, Switzerland.…

BEAM News
Member News
Events

Latest news of BEAM Alliance

02 April 2020 - BEAM Alliance

Request for Proposals (RFP) for an Agreement for Performance of Work (APW) to develop an online e-learning course on antimicrobial stewardship

To support the Antimicrobial Stewardship and Awareness (ASA) Unit in the Global Coordination and Partnership on Antimicrobial Resistance (GCP) department…

03 December 2019 - BEAM Alliance

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

The aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or…

18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

06 June 2019 - BEAM Alliance

Emergency on planet AMR: a vital pipeline to protect

The sooner we come up with practical solutions, the more SMEs (and currently developed products) we can save from vanishing.…

page 1/3

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

29 May 2020 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

18 May 2020 - Nabriva Therapeutics GmbH

National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

14 May 2020 - Polyphor Ltd

Polyphor announces acceptance of balixafortide abstract at the American Society of Clinical Oncology (ASCO) 2020 virtual scientific program

Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer…

06 May 2020 - ANTABIO S.A.S

Antabio Receives QIDP Designation from the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

Martin Everett, Chief Scientific Officer of Antabio said: “The receipt of the QIDP designation is an important regulatory milestone for…

05 May 2020 - Nabriva Therapeutics GmbH

XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)

XENLETA™ is a first-in-class pleuromutilin antibiotic approved by the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired…

05 May 2020 - BioVersys AG

GARDP signs MOU with Swiss biotech BioVersys AG

Marc Gitzinger, CEO and founder of BioVersys said: “We are delighted to enter into this collaboration with GARDP as it…

page 1/19

Events

24 August 2020

4th AMR Conference Novel Antimicrobial & AMR Diagnostics

IMPORTANT UPDATE: Due to the Coronavirus situation, the AMR Conference had to be postponed to 24–25 August in Basel, Switzerland.…

09 July 2020

REVIVE Webinar: The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study

In this webinar, Anand Anandkumar and Kamini Walia will discuss: - Why is India one of the hotbeds of the…

30 June 2020

REVIVE Webinar: Clinical development of antimicrobials – Phase 1 development challenges

Speaker: Markus Zeitlinger, Head of Department of Clinical Pharmacology, Medical University of Vienna (Austria)

25 June 2020

REVIVE Webinar: Putting children first in the fight against antibiotic resistance

Speakers: - Dr Christina Obiero, co-investigator for GARDP fosfomycin clinical trial in Kilifi, Kenya - Dr Manica Balasegaram, Executive Director,…

16 June 2020

REVIVE Webinar: Bringing new treatments for drug-resistant infections to all who need them

The following topics will be presented: - Antibiotic resistance and the GARDP response - Tackling the growing threat of hospital…

09 June 2020

REVIVE Webinar: Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations

Topics discussed will include: - Understanding the inherent challenges associated with PK/PD of BL/BLI combinations - Demonstrating new approaches to…

04 June 2020

Antimicrobial Resistance: The Requirement for a New Business Model for the Development, Production and Sales of New Antibiotics

The online event will look at the requirement for a new business model for the development, production and sales of…

19 May 2020

REVIVE Webinar: Assay development for measuring antibiotic accumulation in Gram-negative bacteria

Assay development for measuring antibiotic accumulation in Gram-negative bacteria

12 May 2020

REVIVE Webinar: Probability of target attainment analyses for dose selection in antimicrobial drug development

Topics discussed will include: - An overview of what is meant by the probability of target attainment (PTA) - How…

page 1/6